The Food and Drug Administration this week approved two abbreviated new drug applications expected to alleviate shortages and help during the COVID-19 emergency.

Dexmedetomidine hydrochloride 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, and sedation of non-intubated patients prior to and/or during surgical and other procedures.

Succinylcholine chloride injection USP 200 mg/10 mL is indicated for general anesthesia, and to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation.

Related News Articles

Headline
An estimated 9.5% of U.S. residents, or 30.7 million people, lacked health insurance when surveyed in the first six months of 2019, according to preliminary…
Headline
The Food and Drug Administration Friday took steps to encourage and streamline the development of COVID-19 tests whose specimens are collected at home by…
Headline
In a letter to the editor, AHA President and CEO Rick Pollack last week responded to a New York Times article titled “Wealthiest Hospitals Got Billions in…
Headline
The AHA is running ads this week in the Politico Pulse newsletter highlighting the unprecedented ways hospitals and health systems have stepped up to meet the…
Headline
The Department of Health and Human Services today announced a $628 million agreement with Emergent BioSolutions to advance manufacturing capabilities and…
Blog
Rick Pollack President and CEO, American Hospital Association Washington, DC COVID-19 has created the greatest financial crisis in history for hospitals and…